A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase 1/2 study will evaluate the safety, tolerance and dose of BM7PE treating patients
with colorectal cancer who have progressed to standard cell therapy or cannot tolerate such
therapy. The study starts as a phase 1 study with the aim of assessing the final dose for
this group of patients. Based on the results, the study will continue into a phase 2. The
phase 2 study aim to examine overall survival ≥ 9.3 months.